Clinical Progress of Fruquintinib in Colorectal Cancer: An Overview
Colorectal cancer (CRC) is one of the most common malignancies worldwide, with high morbidity and mortality rates. Conventional treatments, including surgery, radiotherapy, and chemotherapy, have limited effects on advanced and metastatic CRC (mCRC). Fruquintinib, a novel and highly selective vascul...
Saved in:
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2025-02-01
|
| Series: | Pharmaceuticals |
| Subjects: | |
| Online Access: | https://www.mdpi.com/1424-8247/18/2/280 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1850082091530715136 |
|---|---|
| author | Yejie Xie Shu Tang Ziheng Qin Chaogang Yang |
| author_facet | Yejie Xie Shu Tang Ziheng Qin Chaogang Yang |
| author_sort | Yejie Xie |
| collection | DOAJ |
| description | Colorectal cancer (CRC) is one of the most common malignancies worldwide, with high morbidity and mortality rates. Conventional treatments, including surgery, radiotherapy, and chemotherapy, have limited effects on advanced and metastatic CRC (mCRC). Fruquintinib, a novel and highly selective vascular endothelial growth factor receptor (VEGFR) inhibitor, has shown significant efficacy and tolerance in treating mCRC. The FRESCO and FRESCO-2 trials demonstrated that fruquintinib significantly prolongs progression-free survival and the overall survival of refractory mCRC patients, establishing it as the standard third-line treatment strategy for mCRC. In addition, the combination of fruquintinib with other anticancer drugs and immune checkpoint inhibitors demonstrated potential for enhanced efficacy, which warrants further exploration. In this review, we aimed to systematically summarize the current knowledge about the pharmacological mechanisms, pharmacokinetic characteristics, adverse events, and corresponding treatment options of fruquintinib and provide an update on the clinical trials related to fruquintinib in CRC by conducting a comprehensive literature search of PubMed and consulting the relevant clinical trials via ClinicalTrials.gov and the ChiCTR website, aiming to offer new insights into the role of fruquintinib in the comprehensive treatment of CRC. |
| format | Article |
| id | doaj-art-44f2a3b6f3344857bbeb8405635c35ff |
| institution | DOAJ |
| issn | 1424-8247 |
| language | English |
| publishDate | 2025-02-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Pharmaceuticals |
| spelling | doaj-art-44f2a3b6f3344857bbeb8405635c35ff2025-08-20T02:44:35ZengMDPI AGPharmaceuticals1424-82472025-02-0118228010.3390/ph18020280Clinical Progress of Fruquintinib in Colorectal Cancer: An OverviewYejie Xie0Shu Tang1Ziheng Qin2Chaogang Yang3The Second Clinical School of Wuhan University, Wuhan 430071, ChinaDepartment of Anesthesia and Surgery, Zhongnan Hospital of Wuhan University, Wuhan 430071, ChinaThe Second Clinical School of Wuhan University, Wuhan 430071, ChinaDepartment of Gastrointestinal Surgery, Zhongnan Hospital of Wuhan University, Hubei Key Laboratory of Tumour Biological Behaviours, Hubei Cancer Clinical Study Centre, The Clinical Medical Research Centre of Peritoneal Cancer of Wuhan, Wuhan 430071, ChinaColorectal cancer (CRC) is one of the most common malignancies worldwide, with high morbidity and mortality rates. Conventional treatments, including surgery, radiotherapy, and chemotherapy, have limited effects on advanced and metastatic CRC (mCRC). Fruquintinib, a novel and highly selective vascular endothelial growth factor receptor (VEGFR) inhibitor, has shown significant efficacy and tolerance in treating mCRC. The FRESCO and FRESCO-2 trials demonstrated that fruquintinib significantly prolongs progression-free survival and the overall survival of refractory mCRC patients, establishing it as the standard third-line treatment strategy for mCRC. In addition, the combination of fruquintinib with other anticancer drugs and immune checkpoint inhibitors demonstrated potential for enhanced efficacy, which warrants further exploration. In this review, we aimed to systematically summarize the current knowledge about the pharmacological mechanisms, pharmacokinetic characteristics, adverse events, and corresponding treatment options of fruquintinib and provide an update on the clinical trials related to fruquintinib in CRC by conducting a comprehensive literature search of PubMed and consulting the relevant clinical trials via ClinicalTrials.gov and the ChiCTR website, aiming to offer new insights into the role of fruquintinib in the comprehensive treatment of CRC.https://www.mdpi.com/1424-8247/18/2/280fruquintinibcolorectal cancerVEGFRclinical trialadverse event |
| spellingShingle | Yejie Xie Shu Tang Ziheng Qin Chaogang Yang Clinical Progress of Fruquintinib in Colorectal Cancer: An Overview Pharmaceuticals fruquintinib colorectal cancer VEGFR clinical trial adverse event |
| title | Clinical Progress of Fruquintinib in Colorectal Cancer: An Overview |
| title_full | Clinical Progress of Fruquintinib in Colorectal Cancer: An Overview |
| title_fullStr | Clinical Progress of Fruquintinib in Colorectal Cancer: An Overview |
| title_full_unstemmed | Clinical Progress of Fruquintinib in Colorectal Cancer: An Overview |
| title_short | Clinical Progress of Fruquintinib in Colorectal Cancer: An Overview |
| title_sort | clinical progress of fruquintinib in colorectal cancer an overview |
| topic | fruquintinib colorectal cancer VEGFR clinical trial adverse event |
| url | https://www.mdpi.com/1424-8247/18/2/280 |
| work_keys_str_mv | AT yejiexie clinicalprogressoffruquintinibincolorectalcanceranoverview AT shutang clinicalprogressoffruquintinibincolorectalcanceranoverview AT zihengqin clinicalprogressoffruquintinibincolorectalcanceranoverview AT chaogangyang clinicalprogressoffruquintinibincolorectalcanceranoverview |